Eloxx Pharmaceuticals, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Eloxx Pharmaceuticals, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $0 | Mar 17, 2026 |
| FY2025 | Dec 31, 2024 | $6.36M | Mar 17, 2026 |
| FY2025 | Dec 31, 2023 | $0 | Mar 17, 2026 |
| FY2016 | Jun 30, 2014 | $182.2K | Oct 13, 2016 |
| FY2015 | Jun 30, 2013 | $7.8K | Oct 9, 2015 |
| FY2012 | Jun 30, 2012 | $200.0K | Oct 26, 2012 |
| FY2012 | Jun 30, 2010 | $140.0K | Oct 26, 2012 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($6.00M) | Mar 17, 2026 |
| FY2025 | Dec 31, 2024 | ($3.14M) | Mar 17, 2026 |
| FY2025 | Dec 31, 2023 | ($17.05M) | Mar 17, 2026 |
| FY2022 | Dec 31, 2022 | ($36.07M) | Mar 31, 2023 |
| FY2022 | Dec 31, 2021 | ($66.73M) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | ($34.58M) | Mar 30, 2022 |
| FY2021 | Dec 31, 2019 | ($50.87M) | Mar 30, 2022 |
| FY2020 | Dec 31, 2018 | ($47.19M) | Mar 12, 2021 |
| FY2017 | Dec 31, 2017 | ($10.60M) | Mar 16, 2018 |
| FY2017 | Jun 30, 2017 | ($5.80M) | Oct 13, 2017 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($6.44M) | Mar 17, 2026 |
| FY2025 | Dec 31, 2024 | ($2.47M) | Mar 17, 2026 |
| FY2025 | Dec 31, 2023 | ($17.29M) | Mar 17, 2026 |
| FY2022 | Dec 31, 2022 | ($34.42M) | Mar 31, 2023 |
| FY2022 | Dec 31, 2021 | ($66.02M) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | ($33.46M) | Mar 30, 2022 |
| FY2021 | Dec 31, 2019 | ($50.56M) | Mar 30, 2022 |
| FY2020 | Dec 31, 2018 | ($47.57M) | Mar 12, 2021 |
| FY2019 | Dec 31, 2017 | ($20.39M) | Mar 6, 2020 |
| FY2017 | Jun 30, 2017 | ($4.59M) | Oct 13, 2017 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2020 | Dec 31, 2020 | $14.59M | Mar 12, 2021 |
| FY2020 | Dec 31, 2019 | $26.35M | Mar 12, 2021 |
| FY2020 | Dec 31, 2018 | $20.49M | Mar 12, 2021 |
| FY2017 | Dec 31, 2017 | $8.40M | Mar 16, 2018 |
| FY2017 | Jun 30, 2017 | $733.7K | Oct 13, 2017 |
| FY2018 | Dec 31, 2016 | $8.99M | Mar 14, 2019 |
| FY2017 | Jun 30, 2016 | $2.18M | Oct 13, 2017 |
| FY2017 | Dec 31, 2015 | $5.84M | Mar 16, 2018 |
| FY2017 | Jun 30, 2015 | $4.57M | Oct 13, 2017 |
| FY2016 | Jun 30, 2014 | $3.34M | Oct 13, 2016 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($6.33M) | Mar 17, 2026 |
| FY2025 | Dec 31, 2024 | ($4.72M) | Mar 17, 2026 |
| FY2025 | Dec 31, 2023 | ($14.34M) | Mar 17, 2026 |
| FY2022 | Dec 31, 2022 | ($31.85M) | Mar 31, 2023 |
| FY2022 | Dec 31, 2021 | ($35.00M) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | ($28.17M) | Mar 30, 2022 |
| FY2021 | Dec 31, 2019 | ($39.39M) | Mar 30, 2022 |
| FY2020 | Dec 31, 2018 | ($31.37M) | Mar 12, 2021 |
| FY2017 | Dec 31, 2017 | $6.30M | Mar 16, 2018 |
| FY2018 | Dec 31, 2016 | ($8.84M) | Mar 14, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | $66.0K | Mar 31, 2023 |
| FY2022 | Dec 31, 2021 | $89.0K | Mar 31, 2023 |
| FY2021 | Dec 31, 2019 | $40.0K | Mar 30, 2022 |
| FY2020 | Dec 31, 2018 | $235.0K | Mar 12, 2021 |
| FY2019 | Dec 31, 2017 | $237.0K | Mar 6, 2020 |
| FY2017 | Jun 30, 2017 | $2.5K | Oct 13, 2017 |
| FY2018 | Dec 31, 2016 | $36.0K | Mar 14, 2019 |
| FY2017 | Jun 30, 2016 | $0 | Oct 13, 2017 |
| FY2017 | Dec 31, 2015 | $10.0K | Mar 16, 2018 |
| FY2017 | Jun 30, 2015 | $122.6K | Oct 13, 2017 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $5.27M | Mar 17, 2026 |
| FY2025 | Dec 31, 2024 | $2.98M | Mar 17, 2026 |
| FY2025 | Dec 31, 2023 | $1.71M | Mar 17, 2026 |
| FY2022 | Dec 31, 2022 | $21.12M | Mar 31, 2023 |
| FY2022 | Dec 31, 2021 | $45.14M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $26.48M | Mar 30, 2022 |
| FY2020 | Dec 31, 2019 | $58.95M | Mar 12, 2021 |
| FY2019 | Dec 31, 2018 | $50.72M | Mar 6, 2020 |
| FY2018 | Dec 31, 2017 | $24.78M | Mar 14, 2019 |
| FY2017 | Jun 30, 2017 | $5.85M | Oct 13, 2017 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $17.18M | Mar 17, 2026 |
| FY2025 | Dec 31, 2024 | $27.31M | Mar 17, 2026 |
| FY2025 | Dec 31, 2023 | $24.31M | Mar 17, 2026 |
| FY2022 | Dec 31, 2022 | $31.78M | Mar 31, 2023 |
| FY2022 | Dec 31, 2021 | $22.76M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $16.25M | Mar 30, 2022 |
| FY2020 | Dec 31, 2019 | $22.73M | Mar 12, 2021 |
| FY2019 | Dec 31, 2018 | $7.81M | Mar 6, 2020 |
| FY2017 | Jun 30, 2017 | $4.97M | Oct 13, 2017 |
| FY2017 | Jun 30, 2016 | $4.67M | Oct 13, 2017 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($11.91M) | Mar 17, 2026 |
| FY2025 | Dec 31, 2024 | ($24.34M) | Mar 17, 2026 |
| FY2025 | Dec 31, 2023 | ($22.60M) | Mar 17, 2026 |
| FY2025 | Dec 31, 2022 | ($10.66M) | Mar 17, 2026 |
| FY2022 | Dec 31, 2021 | $22.38M | Mar 31, 2023 |
| FY2022 | Dec 31, 2020 | $10.23M | Mar 31, 2023 |
| FY2021 | Dec 31, 2019 | $36.21M | Mar 30, 2022 |
| FY2021 | Dec 31, 2018 | $42.91M | Mar 30, 2022 |
| FY2020 | Dec 31, 2017 | $21.36M | Mar 12, 2021 |
| FY2017 | Jun 30, 2017 | $871.2K | Oct 13, 2017 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2016 | Jun 30, 2016 | $0 | Oct 13, 2016 |
| FY2016 | Jun 30, 2015 | $5.78M | Oct 13, 2016 |
| FY2017 | Dec 31, 2014 | $13.90M | Oct 13, 2017 |
| FY2015 | Jun 30, 2014 | $13.90M | Oct 9, 2015 |
| FY2014 | Jun 30, 2013 | $0 | Sep 29, 2014 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($300.58M) | Mar 17, 2026 |
| FY2025 | Dec 31, 2024 | ($294.59M) | Mar 17, 2026 |
| FY2025 | Dec 31, 2023 | ($291.44M) | Mar 17, 2026 |
| FY2022 | Dec 31, 2022 | ($274.39M) | Mar 31, 2023 |
| FY2022 | Dec 31, 2021 | ($238.32M) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | ($171.60M) | Mar 30, 2022 |
| FY2020 | Dec 31, 2019 | ($137.02M) | Mar 12, 2021 |
| FY2019 | Dec 31, 2018 | ($86.15M) | Mar 6, 2020 |
| FY2018 | Dec 31, 2017 | ($38.96M) | Mar 14, 2019 |
| FY2017 | Jun 30, 2017 | ($121.82M) | Oct 13, 2017 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.79M | Mar 17, 2026 |
| FY2025 | Dec 31, 2024 | $111.0K | Mar 17, 2026 |
| FY2025 | Dec 31, 2023 | $1.13M | Mar 17, 2026 |
| FY2022 | Dec 31, 2022 | $19.21M | Mar 31, 2023 |
| FY2022 | Dec 31, 2021 | $42.27M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $24.67M | Mar 30, 2022 |
| FY2021 | Dec 31, 2019 | $22.49M | Mar 30, 2022 |
| FY2020 | Dec 31, 2018 | $48.61M | Mar 12, 2021 |
| FY2019 | Dec 31, 2017 | $24.05M | Mar 6, 2020 |
| FY2017 | Jun 30, 2017 | $33.2K | Oct 13, 2017 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.00M | Mar 17, 2026 |
| FY2022 | Dec 31, 2022 | $11.72M | Mar 31, 2023 |
| FY2021 | Dec 31, 2021 | $11.18M | Mar 30, 2022 |
| FY2020 | Dec 31, 2020 | $10.72M | Mar 12, 2021 |
| FY2019 | Dec 31, 2019 | $13.94M | Mar 6, 2020 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 17, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 17, 2026 |
| FY2025 | Dec 31, 2023 | (6) | Mar 17, 2026 |
| FY2022 | Dec 31, 2022 | (16) | Mar 31, 2023 |
| FY2022 | Dec 31, 2021 | (38) | Mar 31, 2023 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 17, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 17, 2026 |
| FY2025 | Dec 31, 2023 | (6) | Mar 17, 2026 |
| FY2022 | Dec 31, 2022 | (16) | Mar 31, 2023 |
| FY2022 | Dec 31, 2021 | (38) | Mar 31, 2023 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 4.79M | Mar 17, 2026 |
| FY2025 | Dec 31, 2024 | 3.53M | Mar 17, 2026 |
| FY2025 | Dec 31, 2023 | 3.14M | Mar 17, 2026 |
| FY2022 | Dec 31, 2022 | 2.17M | Mar 31, 2023 |
| FY2022 | Dec 31, 2021 | 2.17M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | 40.16M | Mar 30, 2022 |
| FY2020 | Dec 31, 2019 | 40.03M | Mar 12, 2021 |
| FY2019 | Dec 31, 2018 | 35.86M | Mar 6, 2020 |
| FY2018 | Dec 31, 2017 | 27.53M | Mar 14, 2019 |
| FY2017 | Jun 30, 2017 | 29.20M | Oct 13, 2017 |